SPARC reports Rs 34 cr operating loss in Q1FY27
Other income of Rs 23.66 cr narrowed the loss but did not prevent a Rs 20.78 cr consolidated net loss.
Filed 10 Aug 2026, 13:34 IST · Sun Pharma Advanced Research Company Ltd (SPARC)
Key takeaways
- SPARC reported a consolidated operating loss of Rs 34 cr in Q1FY27, leaving operating margin at -85.17%.
- Other income of Rs 23.66 cr did not offset the operating loss, and the company reported a net loss of Rs 20.78 cr.
- SPARC's operating margin was 108.12 percentage points below the 22.95% median for 57 reported healthcare peers.
Price around the results
Operating loss dominates the quarter
Consolidated revenue was Rs 39.92 cr against expenses of Rs 73.92 cr, producing an operating loss of Rs 34 cr. Other income of Rs 23.66 cr partly offset this loss, but interest of Rs 8.13 cr and depreciation of Rs 2.20 cr left profit before tax at a loss of Rs 20.67 cr. The company reported a net loss of Rs 20.78 cr and EPS of Rs -0.64.
Margin was far below the healthcare peer median
SPARC's consolidated operating margin of -85.17% was 108.12 percentage points below the 22.95% median among 57 healthcare peers that had reported. The quarter's profit quality was also weak: other income was not enough to reverse the operating loss, while the Rs 0.11 cr tax charge provided no earnings benefit despite the pretax loss.
Shares fell 2.76% on the filing day
SPARC's stock declined 2.76% on 10 August, with trading volume at 1.53 times the reference level. There is no recent-results reaction history in the available record, so this move cannot be classified as ordinary or unusual for the stock.
Q1FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹40 cr |
| Other income | ₹24 cr |
| Expenses | ₹74 cr |
| Operating profit | ₹-34 cr |
| Operating margin (%) | -85.17% |
| Interest | ₹8 cr |
| Depreciation | ₹2 cr |
| Profit before tax | ₹-21 cr |
| Tax | ₹0 cr |
| Net profit | ₹-21 cr |
| EPS (₹) | ₹-0.64 |
Operating margin of -85.17% compares with a Healthcare sector median of 22.95% across 57 peers that have reported Q1FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -2.76% | -2.82% |
Volume on the results session was 1.53× its 20-day average.
What to watch
- Whether revenue moves up from Rs 39.92 cr next quarter.
- Whether operating margin improves from -85.17%.
- Whether other income remains sufficient to narrow the gap between the operating loss of Rs 34 cr and the net loss of Rs 20.78 cr.